| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1a48b04f986c44c2ca9129ce0b1d17c6 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2500-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2896
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P33-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-18 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 |
| filingDate |
2001-09-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c2822ad96da889640e3173fba0b8550d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ef1a62f261516ca3bc4dd9946c71daba
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3ae515917725356dd9af3649d214855a |
| publicationDate |
2003-08-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-1336620-A1 |
| titleOfInvention |
Anti-cd14 monoclonal antibody having effect of inhibiting cd14/tlr binding |
| abstract |
The present invention provides an antibody whichnspecifically recognizes an epitope containing a part of andomain based on a finding that the domain ranging from then269- to 315-positions of human CD14 represented by SEQ IDnNO:1 is a site capable of interacting with another protein,nan antibodies provided. This antibody can inhibit theninteraction between human CD14 and another protein and thusnsuppress cell activation. And also, the present inventionnprovides hybridomas producing the above antibody or itsnfragment; a peptide containing the amino acids in thendomain as specified above; a method of constructing annantibody with the use of this peptide as an immunogen; andna method of screening a medicament for sepsis involving thenstep of bringing a test substance into contact with CD14nand TLR. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7901900-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7465547-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8987425-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7608684-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8124722-B2 |
| priorityDate |
2000-11-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |